| Age | |
| Mean ± SD | 53.0 ± 13.8 |
| Median (IQR) | 51.0 (45.0–64.0) |
| Sex | |
| Men, n (%) | 18 (27) |
| Women, n (%) | 48 (73) |
| Disease duration (in years) | |
| Mean ± SD | 5.90 ± 6.52 |
| Median (IQR) | 4.50 (1.00–9.00) |
| Leroy subset, n (%) | |
| LSSc | 19 (29) |
| LcSSc | 34 (51) |
| DcSSc | 13 (20) |
| NVC pattern, n (%) | |
| Early | 5 (8) |
| Active | 25 (38) |
| Late | 27 (41) |
| Normal — Aspecific changes | 9 (13) |
| Antibodies profile, n (%) | |
| ACA | 23 (35) |
| Anti-topo | 14 (21) |
| Anti-RNA pol III | 7 (11) |
| Pm-Scl | 0 (0) |
| ACA and anti-topo | 1 (1) |
| Peripheral vascular therapy, n (%) “yes” | |
| Prostacyclins | 13 (20) |
| Calcium antagonists | 24 (36) |
| Endothelin receptor antagonists | 0 (0) |
| Phosphodiesterase type 5 inhibitor | 0 (0) |
| Pulmonary-vascular therapy | 0 (0) |
| Prostacyclins | 0 |
| Endothelin receptor antagonists | 0 |
| Phosphodiesterase type 5 inhibitor | 0 |
| Lost to followup, n | 8 |
| Due to logistic reasons | 4 |
| Non-SSc-related reasons | 3 |
| SSc-related reasons* | 1 |
↵* Patient went to another hospital for lung transplantation. NVC: nailfold videocapillaroscopy; IQR: interquartile range; LSSc: limited systemic sclerosis; LcSSc: limited cutaneous systemic sclerosis; DcSSc: diffuse cutaneous systemic sclerosis; ACA: anticentromere antibodies; anti-topo: antitopoisomerase; SSc: systemic sclerosis.